Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ:RLAY)

3.025 +0.025 (+0.83%)
Streaming Delayed Price Updated: 1:54 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Company to host conference call on Wednesday, December 11, 2024 at 7am ET 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Proposed Public Offering of Common Stock
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
Company to disclose new programs from existing unnamed pre-clinical pipeline 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces $30 Million Private Placement Financing
From Relay Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.